| Literature DB >> 33556957 |
Daniel O Griffin1, Denise Brennan-Rieder2, Binh Ngo3, Pierre Kory4, Marco Confalonieri5, Leland Shapiro6, Jose Iglesias7, Michael Dube3, Neha Nanda3, Gino K In3, Daniel Arkfeld3, Preet Chaudhary3, Vito M Campese3, Diana L Hanna3, David Sawcer3, Glenn Ehresmann3, David Peng3, Miroslaw Smorgorzewski3, April Amstrong3, Eivind H Vinjevoll8, Rajkumar Dasgupta3, Fred R Sattler3, Cristina Mussini9, Oriol Mitjà10, Vicente Soriano11, Nicolas Peschanski12, Gilles Hayem13, Maria Carmela Piccirillo14, António Lobo-Ferreira15, Iraldo B Rivero16, Ivan F H Hung17, Marc Rendell18, Stephen Ditmore19, Joseph Varon20, Paul Marik21.
Abstract
COVID-19, caused by SARS-CoV-2, continues to be a major health problem since its first description in Wuhan, China, in December 2019. Multiple drugs have been tried to date in the treatment of COVID-19. Critical to treatment of COVID-19 and advancing therapeutics is an appreciation of the multiple stages of this disease and the importance of timing for investigation and use of various agents. We considered articles related to COVID-19 indexed on PubMed published January 1, 2020-November 15, 2020, and considered papers on the medRxiv preprint server. We identified relevant stages of COVID-19 including three periods: pre-exposure; incubation, and detectable viral replication, and five phases: the viral symptom phase, the early inflammatory phase, the secondary infection phase, the multisystem inflammatory phase, and the tail phase. This common terminology should serve as a framework to guide when COVID-19 therapeutics being studied or currently in use is likely to provide benefit rather than harm.Entities:
Year: 2021 PMID： 33556957 DOI： 10.24875/AIDSRev.200001261
Source DB: PubMed Journal: AIDS Rev ISSN： 1139-6121 Impact factor: 2.500